AVEIR™ LEADLESS
PACEMAKERS
The only leadless solutions that can provide therapy
for all common pacemaker indications1,2,3
THE VENTRICULAR LEADLESS PACEMAKER (LP)
SINGLE HELIX DESIGN FOR VENTRICULAR THERAPY1,6
- 1.63 mm inactive outer helix provides primary fixation
- Electrical mapping prior to fixation
- Recommended implant site: low to mid septal area of the right ventricle
ELECTRICAL PERFORMANCE FROM THE LEADLESS II PHASE 2 STUDY*
Patients with acceptable ventricular device pacing capture threshold and sensing amplitude.14
At just 38.0mm, the AVEIR™ VR FPO Ventricular Leadless Pacemaker (LP) has three time less volume than a standard AAA battery1,6
AVEIR™ VR VENTRICULAR LP IS IMPLANTED IN THE HEART THROUGH A MINIMALLY INVASIVE CATHETER PROCEDURE6
CONNECT patient’s skin electrodes to Merlin™ Patient Care System (PCS) Programmer via AVEIR™ Link Module
INSERT the LP via ergonomic catheter for minimally invasive procedure ensuring helix is fully covered during catheter navigation
MAP atrial implanting location before fixation by touching endocardium with LP’s tip electrode
FIXATE the LP to the atrial endocardium
using the screw-in mechanism
RELEASE the LP and withdraw
delivery catheter
AVEIR™ VR LP14
- Total procedure time: 39.9 ± 21.6 min
- Fluoroscopy time: 9.4 ± 8.5 min
- Repositioning: Avoided in 83% of cases (due to pre-fixation mapping)
PROCEDURE DURATION
Patients with successful ventricular implants (≤1 repositioning attempts)7
RETRIEVAL CATHETER
RETRIEVAL SUCCESS RATES REMAINED HIGH, REGARDLESS OF IMPLANT DURATION15,16*
OVERALL LONG-TERM RETRIEVAL SUCCESS RATE
The AVEIR™ VR Ventricular LP predecessor has a longterm retrieval success rate of 88% with helix fixation through 9 years regardless of implant duration.
RETRIEVAL SUCCESS RATES BY DURATION
INDEPENDENT ATRIAL PACING MODE LONGEVITIES1
AVEIR™ VR VENTRICULAR DEVICE
Parameters: VVI(R), 50 bpm, 500 Ω, models LSP112V/LSP202V
LONGEVITY* (YEARS)
Pulse width
| % PACING | PACE AMPLITUDE | 0.25 ms | 0.4 ms | 0.8 ms |
|---|---|---|---|---|
| 0% | 2.5 V | 27.2 | 27.2 | 27.2 |
| 50% | 1.5 V | 22.9 | 21.1 | 17.9 |
| 2.5 V | 18.1 | 15.2 | 11.3 | |
| 100% | 1.5 V | 19.8 | 17.2 | 13.3 |
| 2.5 V | 13.5 | 10.5 | 7.0 |
Mean ventricular device impedance
at 12-month IDE follow-up10
LONG LASTING
Increased projected battery longevity over currently available leadless pacemakers opens the door to more patients.2,17
Mean ± SD: 17.6 ± 6.6 years18 | 95% Cl: 16.6 to 18.6 years18
BATTERY CAPACITY
At least
1.7x the battery capacity
of current ventricular LPs17,18*
- The average battery longevity among Leadless II phase 2 IDE patients at 1-year follow-up is estimated to be 17.6 years18
- 48% of the study patients have an estimated battery longevity of over 20 years18
AVEIR™ LEADLESS PACEMAKER FOLLOW-UP PROCEDURE
Hear from a cardiac electrophysiologist about the AVEIR™ LP follow-up procedure.
TV
TV
Understanding AVEIR VR Retrieval
Why Leadless Pacing Summit 2026 Matters
AVEIR Atrial LP AAI Implant Training Supplement
AVEIR DR Virtual Implant Training Supplement
Leadless in Congenital Patients
When Patients Evolve: Upgradability in Leadless
Optimizing Tricuspid Valve Crossing: Case example
Optimizing Tricuspid Valve Crossing: Case example
Health Economics of Leadless Therapy
Learn AVEIR Leadless Pacemaker Follow-Up Checks
- AVEIR™ Leadless Pacemakers and Delivery Catheter IFU. ARTEN600361108.
- Micra‡ VR2 MC2VR01 IFU.
- Micra‡ AV2 MC2AVR1 IFU.
- Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. Erratum in: Eur Heart J. 2022 May 1;43(17):1651. doi: 10.1093/eurheartj/ehac075.
- Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):932-987. doi: 10.1016/j.jacc.2018.10.043. Erratum in: J Am Coll Cardiol. 2019;74(7):1014-1016. doi: 10.1016/j.jacc.2019.06.046.
- AVEIR Leadless Pacemakers and Delivery Catheter IFU. ARTEN600175957; ARTEN600307044; ARTEN600361109.
- Knops RE, Reddy VY, Ip JE, et al. A Dual-Chamber Leadless Pacemaker. N Engl J Med. 2023;388(25):2360-2370. doi: 10.1056/NEJMoa2300080.
- Doshi RN, Ip JE, Defaye P, et al. Dual-chamber leadless pacemaker implant procedural outcomes: Insights from the AVEIR DR i2i study. Heart Rhythm. 2025;22(9):2391-2400. doi: 10.1016/j.hrthm.2025.03.1941.
- Knops RE, Ip JE, Doshi R, et al. One-Year Safety and Performance of a Dual-Chamber Leadless Pacemaker. Circ Arrhythm Electrophysiol. 2025;18(4):e013619. doi: 10.1161/CIRCEP.124.013619.
- Knops RE, Ip JE, Doshi R, et al. One-Year Safety and Performance of a Dual-Chamber Leadless Pacemaker. (Supplementary Appendix). Circ Arrhythm Electrophysiol. 2025;18(4):e013619. doi: 10.1161/CIRCEP.124.013619.
- Cantillon D, et al. Percutaneous implantation of a dual-chamber leadless cardiac pacemaker system with bidirectional communication for atrioventricular synchrony. Presented at: Heart Rhythm Society; May 19-21, 2023; New Orleans, USA.
- Nair DG, Lee KW, Badie N, et al. Atrial helix-fixation leadless pacemaker: real-world single-chamber implant experience. J Interv Card Electrophysiol. 2025;68(6):1319-1325. doi: 10.1007/s10840-025-02041-8.
- Ip J, Doshi R, et al. Chronic Retrieval Outcomes for an Atrial Leadless Pacemaker. Presented at: Heart Rhythm Society; Apr 25-27, 2025; San Diego, USA.
- Reddy VY, Exner DV, Doshi R, et al. Primary Results on Safety and Efficacy From the LEADLESS II-Phase 2 Worldwide Clinical Trial. JACC Clin Electrophysiol. 2022;8(1):115-117. doi: 10.1016/j.jacep.2021.11.002.
- Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals: A Worldwide Nanostim Experience out of 9y. Presented at: Asia Pacific Heart Rhythm Society; Nov 18-20, 2022; Singapore.
- Neuzil P, Exner DV, Knops RE, et al. Worldwide Chronic Retrieval Experience of Helix-Fixation Leadless Cardiac Pacemakers. J Am Coll Cardiol. 2025;85(11):1111-1120. doi: 10.1016/j.jacc.2024.10.094.
- AVEIR™ VR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600384624.
- Reddy VY, Exner DV, Doshi R, et al. 1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial. JACC Clin Electrophysiol. 2023;9(7 Pt 2):1187-1189. doi: 10.1016/j.jacep.2023.01.031.
™ indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.